This story was first published May 7.
By Justin Petrone
CombiMatrix's recent restructuring activities and "strong" balance sheet have made the firm a potential buy for companies looking to enter the molecular diagnostics market, according to the firm's top official.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.
It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.
A proposed bill would require NSF to only fund research that's in "the national interest."
Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.